leadf
logo-loader
viewMGC Pharmaceuticals Ltd
(
LSE:MXCOTC:MGCLFFRA:H5OASX:MXC
)

MGC Pharmaceuticals' Roby Zomer says US deal worth at least $24m is 'critical milestone for company'

MGC Pharma PLC (LON:MXC, ASX:MXC) Co-founder and Managing director, Roby Zomer joins Proactive London's Katie Pilbeam to discuss the details of the landmark deal signed with an American drug distributor worth a minimum US$24mln over the next three years.

The tie-up with AMC Holdings will see MGC supplying the phytomedicine products CannEpil, CogniCann and CimetrA for use in clinical trials.

An initial order for US$3mln will be placed five days after a national clinical trial number has been granted. The additional US$21mln will come in years two and three.

Quick facts: MGC Pharmaceuticals Ltd

Follow
LSE:MXC

Price: 3.1 GBX

Market Cap: £73.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC).  The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access...

1 week, 3 days ago

2 min read